Iowa Department of Transportation Major Items - Preliminary Quantity Report, February 17, 2015; With Addendums

Weekly letting report.

Valor energético do óleo ácido de soja para aves

A escassez de valores confiáveis de energia metabolizável tem limitado o uso do óleo ácido de soja como fonte de energia, nas rações de aves. O objetivo deste trabalho foi verificar o efeito da idade da ave e do método de determinação nos valores de energia metabolizável do óleo ácido de soja comercial. No primeiro e segundo ensaios, foi utilizado o método da coleta total de excretas, com pintos de 12 a 20 dias de idade e com galos adultos, respectivamente. No terceiro ensaio, foi utilizado o método Sibbald com galos adultos. Em todos os ensaios, utilizou-se uma ração-referência e uma ração-teste, composta por 10% de óleo ácido de soja e 90% da ração de referência. No método da coleta total de excretas, a energia metabolizável aparente corrigida determinada foi de 7.488 e de 8.610 kcal kg-1 de matéria seca para pintos e galos, respectivamente. A energia metabolizável verdadeira corrigida, determinada pelo método Sibbald, com galos, foi de 8.195 kcal kg-1 de matéria seca. Os valores de energia metabolizável, determinados com galos, foram superiores aos determinados com pintos. Portanto, na formulação de rações para aves, deve-se considerar as diferenças nos valores energéticos do óleo ácido de soja, para aves jovens e adultas.

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.

INTRODUCTION: This trial randomly assessed short-term adjuvant hormonal therapy added to radiotherapy (RT) for intermediate- and high-risk (UICC 1997 cT2a or cT1b-c with high PSA or Gleason score) localised prostate cancer. We report acute toxicity (CTCAE v2) assessed weekly during RT in relation to radiation parameters. PATIENTS AND METHODS: Centres selected the RT dose (70, 74 or 78Gy) and RT technique. Statistical significance is at 0.05. RESULTS: Of 791 patients, 652 received 3D-CRT (70Gy: 195, 74Gy: 376, 78Gy: 81) and 139 received IMRT (74Gy: 28, 78Gy: 111). During RT, grade 3 gastrointestinal (GI) and genitourinary (GU) toxicities were reported by 7 (0.8%) and 50 (6.3%) patients, respectively. No grade 4 was reported. The risk of grade 2 GI toxicity increased significantly with increasing D50%-rectum (p=0.004) and that of grade 2 GU toxicity correlated only to Dmax-bladder (p=0.051). 3D-RT technique, increasing total dose and V95% >400 cc increased D50% and Dmax. One month after RT, only 14 patients (1.8%) reported grade 3 toxicity. AST did not seem to influence the risk of GU or GI acute toxicity. CONCLUSION: RT up to 78Gy was well tolerated. Dmax-bladder and D50%-rectum influenced the risk of grade 2 GU toxicity and GI toxicity, respectively. Both were lower with IMRT but remained high for an irradiated RT volume>400 cc for 3D-RT and for a dose of 78Gy. Hormonal treatment did not influence acute toxicity.

Gestes des rois des Francs (Voy. Bouq., II, 542 Annales de Lauresheim, avec la continuation d'Éginhard (56).

Un auteur liégeois du XVe s. y a intercalé beaucoup d'additions. Au XIV, s. on a ajouté la vie de l'empereur Lucius et de ses successeurs (52v), puis la lettre d'Alexandre à Aristote (53).

Histoire du monastère de Selby, dépendance de Saint-Germain d'Auxerre.

Donné par Châtre de Cangé en 1733, après la vente de ses manuscrits à la Bibliothèque du roi; cf. Catalogue des livres du Cabinet de M..., Paris, 1733, description à la main ajoutée sur les derniers feuillets de garde de plusieurs exemplaires de ce catalogue "Notice de quelques manuscrits d'elite qui n'étoient pas compris dans le catalogue et que M. du Cangé a donnés au roi... Histoire du monastère de Selby, ordre de St Benoît, dans la province d'Yorc. Ce vol. étoit sans inscription et sans n° et vient pourtant du fond de du Cangé"; Delisle, Cab. des mss., I, 411-412; n° 143 de la liste des manuscrits de Cangé établie par Méon; — ex-libris (XVIIe s.)"Monasterii S. Germain Autisiodorensis" de l'abbaye de Saint-Germain d'Auxerre (1), cf. Delisle, Cab. des mss., II, 405.

Latin 11125

Contient : Consolation de Boëce ; Commentaire sur les psaumes

AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

Therapeutic drug monitoring (TDM), i. e., the quantification of serum or plasma concentrations of medications for dose optimization, has proven a valuable tool for the patient-matched psychopharmacotherapy. Uncertain drug adherence, suboptimal tolerability, non-response at therapeutic doses, or pharmacokinetic drug-drug interactions are typical situations when measurement of medication concentrations is helpful. Patient populations that may predominantly benefit from TDM in psychiatry are children, pregnant women, elderly patients, individuals with intelligence disabilities, forensic patients, patients with known or suspected genetically determined pharmacokinetic abnormalities or individuals with pharmacokinetically relevant comorbidities. However, the potential benefits of TDM for optimization of pharmacotherapy can only be obtained if the method is adequately integrated into the clinical treatment process. To promote an appropriate use of TDM, the TDM expert group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued guidelines for TDM in psychiatry in 2004. Since then, knowledge has advanced significantly, and new psychopharmacologic agents have been introduced that are also candidates for TDM. Therefore the TDM consensus guidelines were updated and extended to 128 neuropsychiatric drugs. 4 levels of recommendation for using TDM were defined ranging from "strongly recommended" to "potentially useful". Evidence-based "therapeutic reference ranges" and "dose related reference ranges" were elaborated after an extensive literature search and a structured internal review process. A "laboratory alert level" was introduced, i. e., a plasma level at or above which the laboratory should immediately inform the treating physician. Supportive information such as cytochrome P450 substrate and inhibitor properties of medications, normal ranges of ratios of concentrations of drug metabolite to parent drug and recommendations for the interpretative services are given. Recommendations when to combine TDM with pharmacogenetic tests are also provided. Following the guidelines will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems. Thereby, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profit from such a joint eff ort.